DRIVIN G ROWTH - Dr. Reddy's

schedule to the balance sheet and profit and loss account
Consequent to the adoption of AS 22 – Accounting for Taxes on Income by the Company, with effect from April 1, 2001, the
accumulated deferred tax liability (net) amounting to Rs. 719,030 thousand on account of timing differences between the book
and tax profits up to March 31, 2001 has been debited to the General Reserve Account.
5. EARNINGS PER SHARE
The computation of EPS is set out below:
(Rs. thousand)
For the year ended For the year ended
March 31, 2002 March 31, 2001
Basic & Diluted EPS Basic & Diluted EPS
Earnings
Net profit for the year
Shares
4,596,505 1,444,673
Weighted average number of equity shares outstanding during the year 76,092,181 63,290,948
Earnings per share of face value Rs. 5 60.41 22.83
Outstanding options have an anti-dilutive effect on the EPS for the year ended March 31, 2002. Hence, there is no dilution of EPS
for the year.
Weighted average number of equity shares outstanding during the previous year ended March 31, 2001 have been adjusted for
the share split and restated accordingly. [Refer Note 1 of Schedule 1 (Share Capital)]
6. RELATED PARTY DISCLOSURES
a) There are no related parties where control exists other than in case of subsidiaries including the step-down subsidiaries.
b) Related parties where control exists or with whom transactions have taken place during the year:
Subsidiaries including step-down subsidiaries
� OOO JV Reddy Biomed Limited, Russia;
� Reddy Pharmaceuticals Hong Kong Limited, Hong Kong;
� Dr. Reddy’s Laboratories Inc. (formerly Reddy Cheminor Inc.), USA;
� Reddy Cheminor S.A., France;
� Reddy Antilles N.V., Netherlands;
� Dr. Reddy’s Farmaceutica Do Brazil Ltda., Brazil;
� Zenovus Biotech Private Limited, India;
� Aurigene Discovery Technologies Limited, India;
� Kunshan Rotam Reddy Pharmaceutical Co. Ltd (“Reddy Kunshan”), China;
� Compact Electric Limited, India;
� Cheminor Investments Limited, India;
� DRL Investments Limited, India;
� Reddy Netherlands B.V., Netherlands;
� Reddy Pharmaceuticals Singapore Pte Limited, Singapore;
� Reddy US Therapeutics Inc, USA; and
� Globe Enterprises (a partnership firm in India).
Affiliate
� Pathnet India Private Limited Enterprise where the Company has significant influence
Enterprises where principal shareholders have significant influence (“Significant interest entities”)
� Dr. Reddy’s Research Foundation Enterprise where the principal
(“Research Foundation”) shareholders have significant influence
� Dr. Reddy’s Holdings Limited Enterprise owned by principal shareholders
DR. REDDY’S LABORATORIES LTD. | FINANCIALS | ANNUAL REPORT 2001-2002
125